Peter Hauser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Hauser has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer M. Loftis
VA Portland Health Care System
5 shared publications Shira Kern
Division of Mental Health Long Beach VA Medical Center Long Beach CA USA
4 shared publicationsBret Fuller
Mental Health and Clinical Neurosciences Division Portland VA Medical Center Portland OR USA
3 shared publicationsBenjamin J. Morasco
Mental Health and Clinical Neurosciences Division Portland Health Care System Portland VA USA
2 shared publicationsJennifer Loftis
2 shared publicationsJuan Miranda
2 shared publications
Latest Publications
- 1 September 2018
- Vol. 35 (9) , 36-43
Reducing Benzodiazepine Prescribing in Older Veterans: A Direct-to-Consumer Educational Brochure.
This quality improvement project used an educational brochure to help older veterans reduce their benzodiazepine use.
- 1 September 2018
- Vol. 35 (9) , 36-43
Reducing Benzodiazepine Prescribing in Older Veterans: A Direct-to-Consumer Educational Brochure.
This quality improvement project used an educational brochure to help older veterans reduce their benzodiazepine use.
The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial
Background and Aims: Alcohol use disorders (AUDs) are common among people with chronic hepatitis C (HCV) and accelerate the development of fibrosis and cirrhosis caused by HCV. Baclofen, a gamma‐aminobutyric acid (GABA) beta‐receptor agonist, differs from medications for AUDs currently approved by the United States Food and Drug Administration (FDA), as it is metabolized primarily through the kidneys. The primary outcome of this study was to compare baclofen with a placebo in the percentage of days abstinent from alcohol. Design: A double‐blind, placebo‐controlled randomized trial. Setting: Hepatology clinics in four separate US Veteran Affairs Medical Centers in the United States. Participants: One hundred and eighty Veteran men and women older than 18 years with chronic HCV, a comorbid AUD and current alcohol use. Intervention and Comparator: Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual‐guided counseling. Measurements: The primary measurement was percentage of days abstinent during the 12‐week study period between the baclofen and placebo groups [measured by time‐line follow‐back (TLFB)]. Secondary measurements were the percentage of Veterans who achieved complete abstinence, the percentage of Veterans who achieved no heavy drinking between weeks 4 and 12 of the study, alcohol craving, anxiety, depression and post‐traumatic stress disorder (PTSD). Findings: Primary outcome: compared with placebo, baclofen did not improve the percentage of days abstinent. For all subjects there were significant reductions from baseline to 12 weeks in percentage of days abstinent from 37.0% [standard error (SE) = 2.7] to 68.6% (SE = 2.8, F (1151.1) = 66.1, P < 0.001). However, there was no statistically significant difference between groups for change in percentage of days abstinent over the 12‐week study period [absolute difference 1.3% (−9.1 to 1.7%), F (1152.6) = 0.005, P = 0.95]. Secondary outcomes: Of subjects who completed the first 4 weeks of the study, 8.9% (15 of 168) achieved complete abstinence; 10.1% (nine of 89) in the placebo group and 7.6% (six of 79) in the baclofen group [χ 2 (1) = 0.33, odds ratio (OR) = 0.73 (0.24–2.15)]. The percentage of no heavy drinking for all subjects between weeks 4 and 12 was 20.2% (34 of 168), but no statistically significant differences were found between placebo 15.7% (14 of 89) and baclofen 25.3% (20 of 79) [χ 2 (1) = 2.38, OR = 1.82 (0.85–3.90)]. There were significant reductions for all subjects in all other secondary variables over the course of the study, but no differences between groups. Measures of various biomarkers of alcohol use did not change significantly throughout the course of the study for either the baclofen or placebo groups. Conclusions: Baclofen administered at 30 mg/day does not appear to be superior to placebo in increasing abstinence or in reducing alcohol use, cravings for alcohol or anxiety among people with alcohol use disorder.
The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial
Background and Aims: Alcohol use disorders (AUDs) are common among people with chronic hepatitis C (HCV) and accelerate the development of fibrosis and cirrhosis caused by HCV. Baclofen, a gamma‐aminobutyric acid (GABA) beta‐receptor agonist, differs from medications for AUDs currently approved by the United States Food and Drug Administration (FDA), as it is metabolized primarily through the kidneys. The primary outcome of this study was to compare baclofen with a placebo in the percentage of days abstinent from alcohol. Design: A double‐blind, placebo‐controlled randomized trial. Setting: Hepatology clinics in four separate US Veteran Affairs Medical Centers in the United States. Participants: One hundred and eighty Veteran men and women older than 18 years with chronic HCV, a comorbid AUD and current alcohol use. Intervention and Comparator: Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual‐guided counseling. Measurements: The primary measurement was percentage of days abstinent during the 12‐week study period between the baclofen and placebo groups [measured by time‐line follow‐back (TLFB)]. Secondary measurements were the percentage of Veterans who achieved complete abstinence, the percentage of Veterans who achieved no heavy drinking between weeks 4 and 12 of the study, alcohol craving, anxiety, depression and post‐traumatic stress disorder (PTSD). Findings: Primary outcome: compared with placebo, baclofen did not improve the percentage of days abstinent. For all subjects there were significant reductions from baseline to 12 weeks in percentage of days abstinent from 37.0% [standard error (SE) = 2.7] to 68.6% (SE = 2.8, F (1151.1) = 66.1, P < 0.001). However, there was no statistically significant difference between groups for change in percentage of days abstinent over the 12‐week study period [absolute difference 1.3% (−9.1 to 1.7%), F (1152.6) = 0.005, P = 0.95]. Secondary outcomes: Of subjects who completed the first 4 weeks of the study, 8.9% (15 of 168) achieved complete abstinence; 10.1% (nine of 89) in the placebo group and 7.6% (six of 79) in the baclofen group [χ 2 (1) = 0.33, odds ratio (OR) = 0.73 (0.24–2.15)]. The percentage of no heavy drinking for all subjects between weeks 4 and 12 was 20.2% (34 of 168), but no statistically significant differences were found between placebo 15.7% (14 of 89) and baclofen 25.3% (20 of 79) [χ 2 (1) = 2.38, OR = 1.82 (0.85–3.90)]. There were significant reductions for all subjects in all other secondary variables over the course of the study, but no differences between groups. Measures of various biomarkers of alcohol use did not change significantly throughout the course of the study for either the baclofen or placebo groups. Conclusions: Baclofen administered at 30 mg/day does not appear to be superior to placebo in increasing abstinence or in reducing alcohol use, cravings for alcohol or anxiety among people with alcohol use disorder.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1161-S1162
S100B Levels in Blood as a Potential Marker of Blood Brain Barrier Damage and Neuropsychiatric Impairment in Co-Morbid HCV and Alcohol Use Disorder
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1161-S1162
S100B Levels in Blood as a Potential Marker of Blood Brain Barrier Damage and Neuropsychiatric Impairment in Co-Morbid HCV and Alcohol Use Disorder
- Open Access
- 29 July 2016
- Published by Bentham Science Publishers Ltd. in Open Medicine Journal
- Vol. 3 (1) , 79-103
Co-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C
Chronic infection with Hepatitis C virus (HCV) is common and can result in serious and sometimes fatal liver complications. The impact of HCV on the liver can be further complicated by medical and psychological comorbidities. Depression, substance use, and pain syndromes are frequent co-morbid conditions in people with HCV and diminish functioning, quality of life, and treatment compliance. Understanding the underlying biological mechanisms of these comorbid conditions within the context of HCV may help elucidate factors contributing to their co-occurrence, perhaps mediatedviapro-inflammatory cytokines. The current review provides a synthesis of the literature on depression, substance use disorders and chronic pain in the presence of HCV. The review includes studies conducted with both veteran and civilian populations. The implications for assessment and antiviral treatment of HCV will be considered.
- 29 July 2016
- Published by Bentham Science Publishers Ltd. in Open Medicine Journal
- Vol. 3 (1) , 79-103
Open AccessCo-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C
Chronic infection with Hepatitis C virus (HCV) is common and can result in serious and sometimes fatal liver complications. The impact of HCV on the liver can be further complicated by medical and psychological comorbidities. Depression, substance use, and pain syndromes are frequent co-morbid conditions in people with HCV and diminish functioning, quality of life, and treatment compliance. Understanding the underlying biological mechanisms of these comorbid conditions within the context of HCV may help elucidate factors contributing to their co-occurrence, perhaps mediatedviapro-inflammatory cytokines. The current review provides a synthesis of the literature on depression, substance use disorders and chronic pain in the presence of HCV. The review includes studies conducted with both veteran and civilian populations. The implications for assessment and antiviral treatment of HCV will be considered.
- Open Access
- 29 July 2016
- Published by Bentham Science Publishers Ltd. in Open Medicine Journal
- Vol. 3 (1) , 49-51
Hepatitis C and Psychiatric and Substance Use Disorders Co-morbidities; Caring for People with Hepatitis C: Lessons from the Past that Inform Expectations in the Future
Hepatitis C and Psychiatric and Substance Use Disorders Co-morbidities; Caring for People with Hepatitis C: Lessons from the Past that Inform Expectations in the Future
- 29 July 2016
- Published by Bentham Science Publishers Ltd. in Open Medicine Journal
- Vol. 3 (1) , 49-51
Open AccessHepatitis C and Psychiatric and Substance Use Disorders Co-morbidities; Caring for People with Hepatitis C: Lessons from the Past that Inform Expectations in the Future
Hepatitis C and Psychiatric and Substance Use Disorders Co-morbidities; Caring for People with Hepatitis C: Lessons from the Past that Inform Expectations in the Future
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1044
654 Baclofen Treatment for Alcohol Dependence in Patients With Chronic HCV Liver Disease: A Multicenter Randomized Clinical Trial
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1044
654 Baclofen Treatment for Alcohol Dependence in Patients With Chronic HCV Liver Disease: A Multicenter Randomized Clinical Trial
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (15) , 1921-35
Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications
Chronic hepatitis C virus (HCV) viral infection is the most common blood-borne viral infection and approximately 2%-3% of the world's population or 170-200 million people are infected. In the United States as many as 3-5 million people may have HCV. Psychiatric and substance use disorders (SUDs) are common co-morbid conditions found in people with HCV and are factors in predisposing people to HCV infection. Also, these co-morbidities are reasons that clinicians exclude people from antiviral therapy in spite of evidence that people with HCV and co-morbid psychiatric and SUD can be safely and effectively treated. Furthermore, the neuropsychiatric side effects of interferon (IFN), until recently the mainstay of antiviral therapy, have necessitated an appreciation and assessment of psychiatric co-morbidities present in people with HCV. The availability of new medications and IFN-free antiviral therapy medication combinations will shorten the duration of treatment and exposure to IFN and thus decrease the risk of neuropsychiatric side effects. This will have the consequence of dramatically altering the clinical landscape of HCV care and will increase the number of eligible treatment candidates as treatment of people with HCV and co-morbid psychiatric and SUDs will become increasingly viable. While economically developed countries will rely on expensive IFN-free antiviral therapy, less developed countries will likely continue to use IFN-based therapies at least until such time as IFN-free antiviral medications become generic. The current manuscript discusses the efficacy and viability of treating HCV in people with psychiatric and SUDs comorbidities, the treatment of the neuropsychiatric side effects of IFN -based therapies and the impact of new medications and new treatment options for HCV that offer the promise of increasing the availability of antiviral therapy in this vulnerable population.
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (15) , 1921-35
Open AccessPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications
Chronic hepatitis C virus (HCV) viral infection is the most common blood-borne viral infection and approximately 2%-3% of the world's population or 170-200 million people are infected. In the United States as many as 3-5 million people may have HCV. Psychiatric and substance use disorders (SUDs) are common co-morbid conditions found in people with HCV and are factors in predisposing people to HCV infection. Also, these co-morbidities are reasons that clinicians exclude people from antiviral therapy in spite of evidence that people with HCV and co-morbid psychiatric and SUD can be safely and effectively treated. Furthermore, the neuropsychiatric side effects of interferon (IFN), until recently the mainstay of antiviral therapy, have necessitated an appreciation and assessment of psychiatric co-morbidities present in people with HCV. The availability of new medications and IFN-free antiviral therapy medication combinations will shorten the duration of treatment and exposure to IFN and thus decrease the risk of neuropsychiatric side effects. This will have the consequence of dramatically altering the clinical landscape of HCV care and will increase the number of eligible treatment candidates as treatment of people with HCV and co-morbid psychiatric and SUDs will become increasingly viable. While economically developed countries will rely on expensive IFN-free antiviral therapy, less developed countries will likely continue to use IFN-based therapies at least until such time as IFN-free antiviral medications become generic. The current manuscript discusses the efficacy and viability of treating HCV in people with psychiatric and SUDs comorbidities, the treatment of the neuropsychiatric side effects of IFN -based therapies and the impact of new medications and new treatment options for HCV that offer the promise of increasing the availability of antiviral therapy in this vulnerable population.
- Open Access
- 20 August 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (10) , 2753-5
Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.
- 20 August 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (10) , 2753-5
Open AccessPain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.
- 1 January 2013
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 74 (1) , 57-63
Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study
- 1 January 2013
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 74 (1) , 57-63
Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study
- Open Access
- 4 November 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (4) , 1413-1414
Depression and antiviral response to interferon-based therapy for hepatitis C virus infection
- 4 November 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (4) , 1413-1414
Open AccessDepression and antiviral response to interferon-based therapy for hepatitis C virus infection